Literature DB >> 12496218

Treatment of neonatal abstinence syndrome.

K Johnson1, C Gerada, A Greenough.   

Abstract

Neonatal abstinence syndrome (NAS) is suffered by infants withdrawing from substances on which they have become physically dependent after in utero exposure. They may require prolonged treatment and spend weeks or even months in hospital. A wide range of drugs have been used to treat NAS. The efficacy of few, however, have been adequately investigated. Evidence suggests that opioids are the most appropriate, at least in infants exposed to diamorphine or methadone. In all "head to head" trials, diazepam has been shown to be ineffective. Morphine and methadone are currently the most commonly prescribed opioids to treat NAS, but randomised trials have not been undertaken to determine which is the more beneficial. Many infants with NAS have been exposed to multiple substances in utero. Further research is required into whether a single opiate or a multiple drug regimen is the best option for such patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496218      PMCID: PMC1756008          DOI: 10.1136/fn.88.1.f2

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  47 in total

1.  Anonymous testing for drug abuse in an antenatal population.

Authors:  A G Farkas; D L Colbert; K J Erskine
Journal:  Br J Obstet Gynaecol       Date:  1995-07

2.  Methadone maintenance in pregnancy: consequences to care and outcome.

Authors:  K C Edelin; L Gurganious; K Golar; D Oellerich; K Kyei-Aboagye; M Adel Hamid
Journal:  Obstet Gynecol       Date:  1988-03       Impact factor: 7.661

3.  An evaluation of neonatal abstinence treatment modalities.

Authors:  L P Finnegan; H Michael; B Leifer; S Desai
Journal:  NIDA Res Monogr       Date:  1984-03

4.  Neonatal methadone withdrawal. Effect of two treatment regimens.

Authors:  I Carin; L Glass; A Parekh; N Solomon; J Steigman; S Wong
Journal:  Am J Dis Child       Date:  1983-12

5.  Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus.

Authors:  R S Duman; J F Tallman; E J Nestler
Journal:  J Pharmacol Exp Ther       Date:  1988-09       Impact factor: 4.030

6.  Effects of in utero substance exposure on infant neurobehavior.

Authors:  B Napiorkowski; B M Lester; M C Freier; S Brunner; L Dietz; A Nadra; W Oh
Journal:  Pediatrics       Date:  1996-07       Impact factor: 7.124

7.  Neonatal abstinence syndrome, pharmacotherapy and developmental outcome.

Authors:  K Kaltenbach; L P Finnegan
Journal:  Neurobehav Toxicol Teratol       Date:  1986 Jul-Aug

8.  Clonidine treatment of neonatal narcotic abstinence syndrome.

Authors:  E L Hoder; J F Leckman; J Poulsen; K A Caruso; R A Ehrenkranz; H D Kleber; D J Cohen
Journal:  Psychiatry Res       Date:  1984-11       Impact factor: 3.222

9.  Role of noradrenergic hyperactivity in neonatal opiate abstinence.

Authors:  P J Little; R R Price; R K Hinton; C M Kuhn
Journal:  Drug Alcohol Depend       Date:  1996-05       Impact factor: 4.492

10.  Neurologic manifestations of in utero cocaine exposure in near-term and term infants.

Authors:  T A King; J M Perlman; A R Laptook; N Rollins; G Jackson; B Little
Journal:  Pediatrics       Date:  1995-08       Impact factor: 7.124

View more
  10 in total

1.  Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Authors:  Walter K Kraft; Kevin Dysart; Jay S Greenspan; Eric Gibson; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Addiction       Date:  2010-10-06       Impact factor: 6.526

Review 2.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

3.  Neonatal abstinence syndrome--postnatal ward versus neonatal unit management.

Authors:  Tolulope Saiki; Silke Lee; Simon Hannam; Anne Greenough
Journal:  Eur J Pediatr       Date:  2009-05-14       Impact factor: 3.183

4.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Authors:  Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Pediatrics       Date:  2008-08-11       Impact factor: 7.124

5.  Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.

Authors:  Alexander G Agthe; George R Kim; Kay B Mathias; Craig W Hendrix; Raul Chavez-Valdez; Lauren Jansson; Tamorah R Lewis; Myron Yaster; Estelle B Gauda
Journal:  Pediatrics       Date:  2009-04-27       Impact factor: 7.124

Review 6.  The opioid-exposed newborn: assessment and pharmacologic management.

Authors:  Lauren M Jansson; Martha Velez; Cheryl Harrow
Journal:  J Opioid Manag       Date:  2009 Jan-Feb

7.  Three patients and their drugs: A parallel case paper on paediatric opiate use and withdrawal.

Authors:  Harold B Siden; Kathleen Collin
Journal:  Paediatr Child Health       Date:  2005-03       Impact factor: 2.253

8.  Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea.

Authors:  Anthony Liu; Tracey Björkman; Caroline Stewart; Ralph Nanan
Journal:  Int J Pediatr       Date:  2011-05-23

9.  Substance abuse in pregnancy: opioid substitution in a northern Ireland maternity unit.

Authors:  Sandra Mawhinney; Robin G Ashe; Joanne Lowry
Journal:  Ulster Med J       Date:  2006-09

Review 10.  The Mechanisms Involved in Morphine Addiction: An Overview.

Authors:  Joanna Listos; Małgorzata Łupina; Sylwia Talarek; Antonina Mazur; Jolanta Orzelska-Górka; Jolanta Kotlińska
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.